Navigation Links
Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
Date:2/24/2011

BLUE BELL, Pa., Feb. 24, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO will present a company overview at the Cowen & Co. 31st Annual Health Care Conference being held March 7-9 at the Boston Marriott Copley Place in Boston, MA.

Inovio Presentation: March 9, 2011 at 8:00 am ESThttp://www.cowen.com/UpcomingConferences.html

About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.CONTACTS:Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.comMedia:   Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com(Logo:  http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)


'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
2. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
5. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
6. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
7. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
8. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
9. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment ... in 2021, according to Medical Equipment & ... by Freedonia Focus Reports. Continued increases in demand for ... aging of the population and supported by gains in ... equipment and supplies. New product introductions will also drive ...
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , M.D., ... Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . Dr. ... Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., who ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cosmetic Town, an online plastic surgery information ... they perform on a daily basis. , The new video series will feature ... in at their practices. , When asked about the new video series, the ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... partnered together for a unique opportunity that helps high school girls succeed in ... Barriers, Creating Opportunities.” Horizon Goodwill will host over 20 high school girls ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... scholarship awards to be awarded annually to and divided between two full-time university ... bringing awareness to Amazonian plant medicine. To apply for the scholarship, students are ...
(Date:7/24/2017)... ... , ... Every year, thousands of dedicated Higher Education and K12 professionals flock ... coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to take ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs secured ...
Breaking Medicine News(10 mins):